Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin's lymphoma that affects the T-cells in the immune system and appears on the skin as lesions, tumors, or plaques. About 20,000 people in the U.S. are believed to have CTCL, with similar numbers in Europe and significant cases in Asia. The majority of patients with CTCL have early-stage disease (called Mycosis Fungoides), which, with careful disease management, may never progress to later stages of disease. However, there is NO FDA-approved first-line therapy for early-stage CTCL.
The company we are profiling today is Soligenix Inc. (SNGX), which is developing a safer, more convenient alternative to commonly used approaches for early-stage CTCL.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.